|
1
|
Linardou H, Dahabreh IJ, Kanaloupiti D, et
al: Assessment of somatic k-RAS mutations as a mechanism associated
with resistance to EGFR-targeted agents: a systematic review and
meta-analysis of studies in advanced non-small-cell lung cancer and
metastatic colorectal cancer. Lancet Oncol. 9:962–972. 2008.
View Article : Google Scholar
|
|
2
|
Normanno N, Tejpar S, Morgillo F, De Luca
A, Van Cutsem E and Ciardiello F: Implications for KRAS
status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin
Oncol. 6:519–527. 2009.
|
|
3
|
Messner I, Cadeddu G, Huckenbeck W,
Knowles HJ, Gabbert HE, Baldus SE and Schaefer KL: KRAS p.
G13D mutations are associated with sensitivity to anti-EGFR
antibody treatment in colorectal cancer cell lines. J Cancer Res
Clin Oncol. 139:201–209. 2013. View Article : Google Scholar
|
|
4
|
Loupakis F, Pollina L, Stasi I, et al:
PTEN expression and KRAS mutations on primary tumors and
metastases in the prediction of benefit from cetuximab plus
irinotecan for patients with metastatic colorectal cancer. J Clin
Oncol. 27:2622–2629. 2009.PubMed/NCBI
|
|
5
|
Saridaki Z, Tzardi M, Papadaki C, et al:
Impact of KRAS, BRAF, PIK3CA mutations,
PTEN, AREG, EREG expression and skin rash in ≥
2 line cetuximab-based therapy of colorectal cancer patients. PLoS
One. 6:e159802011.
|
|
6
|
O’Neil BH: Systemic therapy for colorectal
cancer: focus on newer chemotherapy and novel agents. Semin Radiat
Oncol. 13:441–453. 2003.PubMed/NCBI
|
|
7
|
Adlard JW, Richman SD, Seymour MT and
Quirke P: Prediction of the response of colorectal cancer to
systemic therapy. Lancet Oncol. 3:75–82. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Benvenuti S, Sartore-Bianchi A, Di
Nicolantonio F, et al: Oncogenic activation of the RAS/RAF
signaling pathway impairs the response of metastatic colorectal
cancers to anti-epidermal growth factor receptor antibody
therapies. Cancer Res. 67:2643–2648. 2007. View Article : Google Scholar
|
|
9
|
Bando H, Yoshino T, Yuki S, et al:
Clinical outcome of Japanese metastatic colorectal cancer patients
harbouring the KRAS p. G13D mutation treated with cetuximab
+ irinotecan. Jpn J Clin Oncol. 42:1146–1151. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tejpar S, Celik I, Schlichting M,
Sartorius U, Bokemeyer C and Van Cutsem E: Association of
KRAS G13D tumor mutations with outcome in patients with
metastatic colorectal cancer treated with first-line chemotherapy
with or without cetuximab. J Clin Oncol. 30:3570–3577.
2012.PubMed/NCBI
|
|
11
|
Guerrero S, Casanova I, Farré L, Mazo A,
Capellà G and Mangues R: K-ras codon 12 mutation induces higher
level of resistance to apoptosis and predisposition to
anchorage-independent growth than codon 13 mutation or
proto-oncogene overexpression. Cancer Res. 60:6750–6756. 2000.
|
|
12
|
De Roock W, Jonker DJ, Di Nicolantonio F,
et al: Association of KRAS p. G13D mutation with outcome in
patients with chemotherapy-refractory metastatic colorectal cancer
treated with cetuximab. JAMA. 304:1812–1820. 2010.
|
|
13
|
Peeters M, Douillard JY, Van Cutsem E,
Siena S, Zhang K, Williams R and Wiezorek J: Mutant KRAS
codon 12 and 13 alleles in patients with metastatic colorectal
cancer: assessment as prognostic and predictive biomarkers of
response to panitumumab. J Clin Oncol. 31:759–765. 2013.
|
|
14
|
Gajate P, Sastre J, Bando I, et al:
Influence of KRAS p. G13D mutation in patients with
metastatic colorectal cancer treated with cetuximab. Clin
Colorectal Cancer. 11:291–296. 2012.
|
|
15
|
Di Nicolantonio F, Martini M, Molinari F,
et al: Wild-type BRAF is required for response to
panitumumab or cetuximab in metastatic colorectal cancer. J Clin
Oncol. 26:5705–5712. 2008.
|
|
16
|
Ulivi P, Capelli L, Valgiusti M, et al:
Predictive role of multiple gene alterations in response to
cetuximab in metastatic colorectal cancer: a single center study. J
Transl Med. 10:872012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kato S, Iida S, Higuchi T, et al:
PIK3CA mutation is predictive of poor survival in patients
with colorectal cancer. Int J Cancer. 121:1771–1778. 2007.
View Article : Google Scholar
|
|
18
|
Inno A, Di Salvatore M, Cenci T, et al: Is
there a role for IGF1R and c-MET pathways in resistance to
cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer.
10:325–332. 2011. View Article : Google Scholar
|
|
19
|
Guo A, Villén J, Kornhauser J, et al:
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl
Acad Sci USA. 105:692–697. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sattler M, Reddy MM, Hasina R, Gangadhar T
and Salgia R: The role of the c-Met pathway in lung cancer and the
potential for targeted therapy. Ther Adv Med Oncol. 3:171–184.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
22
|
Ohnishi H, Ohtsuka K, Ooide A, Matsushima
S, Goya T and Watanabe T: A simple and sensitive method for
detecting major mutations within the tyrosine kinase domain of the
epidermal growth factor receptor gene in non-small-cell lung
carcinoma. Diagn Mol Pathol. 15:101–108. 2006. View Article : Google Scholar
|
|
23
|
Torres J, Navarro S, Roglá I, et al:
Heterogeneous lack of expression of the tumour suppressor PTEN
protein in human neoplastic tissues. Eur J Cancer. 37:114–121.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dua R, Zhang J, Parry G and Penuel E:
Detection of hepatocyte growth factor (HGF) ligand-c-MET receptor
activation in formalin-fixed paraffin embedded specimens by a novel
proximity assay. PLoS One. 6:e159322011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Murray S, Karavasilis V, Bobos M, et al:
Molecular predictors of response to tyrosine kinase inhibitors in
patients with non-small-cell lung cancer. J Exp Clin Cancer Res.
31:772012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin B, Utleg AG, Gravdal K, et al: WDR19
expression is increased in prostate cancer compared with normal
cells, but low-intensity expression in cancers is associated with
shorter time to biochemical failures and local recurrence. Clin
Cancer Res. 14:1397–1406. 2008. View Article : Google Scholar
|
|
27
|
Halvorsen OJ, Rostad K, Øyan AM, et al:
Increased expression of SIM2-s protein is a novel marker of
aggressive prostate cancer. Clin Cancer Res. 13:892–897. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zeng ZL, Wu WJ, Yang J, et al: Prognostic
relevance of melanoma antigen D1 expression in colorectal
carcinoma. J Transl Med. 10:1812012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pandolfi PP: Breast cancer - loss of PTEN
predicts resistance to treatment. N Engl J Med. 351:2337–2338.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jo M, Stolz DB, Esplen JE, Dorko K,
Michalopoulos GK and Strom SC: Cross-talk between epidermal growth
factor receptor and c-Met signal pathways in transformed cells. J
Biol Chem. 275:8806–8811. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takeuchi H, Bilchik A, Saha S, et al:
c-MET expression level in primary colon cancer: a predictor of
tumor invasion and lymph node metastases. Clin Cancer Res.
9:1480–1488. 2003.
|
|
32
|
Trusolino L and Comoglio PM:
Scatter-factor and semaphorin receptors: cell signalling for
invasive growth. Nat Rev Cancer. 2:289–300. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kiaris H and Spandidos DA: Mutations of
ras genes in human tumours (Review). Int J Oncol. 7:413–421.
1995.
|
|
34
|
Mao C, Huang YF, Yang ZY, Zheng DY, Chen
JZ and Tang JL: KRAS p. G13D mutation and codon 12 mutations
are not created equal in predicting clinical outcomes of cetuximab
in metastatic colorectal cancer: A systematic review and
meta-analysis. Cancer. 119:714–721. 2013. View Article : Google Scholar
|
|
35
|
Strumberg D, Scheulen ME, Schultheis B, et
al: Regorafenib (BAY 73-4506) in advanced colorectal cancer: a
phase I study. Br J Cancer. 106:1722–1727. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Van Cutsem E, Tabernero J, Lakomy R, et
al: Addition of aflibercept to fluorouracil, leucovorin, and
irinotecan improves survival in a phase III randomized trial in
patients with metastatic colorectal cancer previously treated with
an oxaliplatin-based regimen. J Clin Oncol. 30:3499–3506. 2012.
|
